Infinity Announces Phase I Data from IPI-145 Against R/R Lymphomas

At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Infinity Pharmaceuticals announced updated Phase 1 data from an ongoing study of IPI-145, the company's potent oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients diagnosed with relapsed or refractory B-cell or T-cell non-Hodgkin's lymphoma as well as Hodgkin's lymphoma.

Preliminary data indicates that IPI-145 is both well-tolerated and clinically active in patients with subtypes including some indolent non-Hodgkin's lymphomas, T-cell lymphoma, mantle cell lymphoma (MCL) and Hodgkin's lymphoma (HL).

Said trial investigator Steven Horwitz, MD, assistant attending physician in the department of medicine at the Memorial Sloan-Kettering Cancer Center:

I’m encouraged by the early data seen in this Phase 1 study of IPI-145. So far, IPI-145 appears to be well tolerated, with responses seen across a broad range of B-cell and T-cell lymphomas. Many hematologic malignancies are difficult to treat and new agents are clearly needed. Targeted therapies, including IPI-145, have the potential not only to add therapeutic options for our patients but also to reduce or delay the need for chemotherapy, possibly changing the way many of these malignancies are treated.

It wasn't Infinity's only presentation. The company also announced that that its Phase 2 study of IPI-145 in hematologic malignancies is open for enrollment. This trial will be a Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of IPI-145. They are looking to enroll 120 patients with refractory indolent non-Hodgkin's lymphomas, since data from the Phase 1 study showed that 13 of 19 patients with indolent NHLs had responses to IPI-145, including three who had complete responses.

Said Julian Adams, PhD, president of research and development at Infinity:

Infinity is pleased to begin its first Phase 2 study of IPI-145 in patients with indolent non-Hodgkin lymphoma, which is supported by the early, encouraging, data from our ongoing Phase 1 study reported today at ASCO. Infinity believes IPI-145 has the potential to be the best-in-class PI3K inhibitor for the treatment of blood cancers, and we are rapidly advancing IPI-145 in the clinic with a goal of addressing significant medical needs.

Source: ASCO '13

More Articles

More Articles

This article looks at the Non-Hodgkin's Lymphoma survival rate as well as the Non-Hodgkin's Lymphoma mortality rate ....

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...